ESC 365 - Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?

HFA Premium Access

Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?

Session: Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death

Topic: Treatment

Speaker: Professor C. Veltmann (Bremen, DE)

Sponsored by Zoll

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Professor Christian Veltmann

Heart Center Bremen, Bremen (Germany)

10 presentations

7 followers

4 more presentations in this session

Introduction - Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death

Speaker: Professor L. Kober (Copenhagen, DK)

Taking your time in the treatment of newly diagnosed heart failure patients.

Speaker: Doctor J. Erath (Frankfurt, DE)

The impact of the WCD for patients who choose to wear it.

Speaker: Professor A. Flammer (Zurich, CH)

Panel discussion and summary - Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death.

Speaker: Professor C. Leclercq (Rennes, FR)

Access the full session

Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death

Speakers: Professor C. Veltmann, Professor L. Kober, Doctor J. Erath, Professor A. Flammer, Professor C. Leclercq

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources